Comparative Pharmacology
Head-to-head clinical analysis: FUROXONE versus IMPAVIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUROXONE versus IMPAVIDO.
FUROXONE vs IMPAVIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Furazolidone is a nitrofuran antimicrobial that inhibits bacterial monoamine oxidase and disrupts bacterial DNA synthesis by undergoing reduction by bacterial nitroreductases to reactive intermediates that cause DNA cross-linking and damage.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
100 mg orally four times daily
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours; clinically, this supports dosing every 6 hours for sustained antibacterial effect.
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Primarily renal (approximately 65%) as unchanged drug; biliary/fecal excretion accounts for about 35%.
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Category C
Category C
Antibacterial/Antiprotozoal
Antiprotozoal